CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Laboratory services:
Drugs-of-abuse testing services	$ 10,578	$ 9,640
Clinical & other laboratory services:
Other clinical and laboratory services	5,486	4,740
Net patient services, less provision for bad debts of $738 in 2012 and $639 in 2011	3,699	2,596
Total Clinical & other laboratory services	9,185	7,336
Clinical trial services	2,374	2,536
Product sales	6,443	5,585
Total revenues	28,580	25,097
COST OF REVENUES:
Cost of services	14,050	12,952
Cost of sales	2,674	2,333
Total cost of revenues	16,724	15,285
GROSS PROFIT	11,856	9,812
OPERATING EXPENSES:
Selling, general and administrative	8,807	7,985
Research and development	689	594
Total operating expenses	9,496	8,579
INCOME FROM OPERATIONS	2,360	1,233
OTHER INCOME (EXPENSE):
Interest expense	0	(24)
Other (expense) income	(4)	16
Total other (expense) income	(4)	(8)
INCOME BEFORE INCOME TAX EXPENSE	2,356	1,225
INCOME TAX EXPENSE	(860)	(447)
NET INCOME	$ 1,496	$ 778
BASIC EARNINGS PER COMMON SHARE	$ 0.17	$ 0.09
DILUTED EARNINGS PER COMMON SHARE	$ 0.17	$ 0.09
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:
Basic	8,875,786	8,850,228
Diluted	9,065,565	9,043,757